Performance in Initiating Clinical Research - Quarter 1 (2022/23)

All clinical trials hosted between 01 July 2021 to 31 June 2022

HRA Approval studies

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Participant Recruited	Comments	Reasons for Delay correspond to
21/FT/0048	289818	M19-977	24/03/2021	26/08/2021	14/06/2021	17/09/2021	27/09/2021	04/10/2021	29/10/2021	None.	Please Select
21/LO/0456	299310	SYMPLIFY	31/08/2021	31/08/2021	24/06/2021	30/09/2021	30/09/2021	05/10/2021	05/10/2021	Updated from last submission. Incorrect Rec reference, this has now been rectified.	Please Select
18/YH/0013	214831	The DUAL-ACS2 Trial	03/06/2021	05/07/2021	22/07/2020	05/08/2021	05/08/2021	13/08/2021	20/08/2021	None.	Please Select
19/YH/0015	255446	Beta-blockers or placebo for primary prophylaxis (BOPPP) Trial	03/10/2019	03/09/2021	24/04/2019	27/09/2021	01/10/2021	19/10/2021	31/01/2022	Patients screened failed to meet criteria in the last update. First patient has now been recruited to the study.	Neither
20/SC/0372	283157	CRASH-4	01/07/2021	19/07/2021	17/12/2020	03/09/2021	23/09/2021	28/09/2021	30/11/2021	We received the local information pack from the sponsor during the feasibility stage. The feasibility form was completed and sent back after receiving the LIP. First Patient recruitment has now happened	Please Select
19/EM/0253	263682	Routine testing for Group B Streptococcus	19/12/2019	15/09/2021	23/10/2019	15/07/2021	22/10/2021	02/12/2021	12/01/2022	None.	Please Select
21/FT/0081	295684	PRIOH-1	06/07/2021	21/07/2021	09/08/2021	15/11/2021	20/12/2021	15/12/2021	03/02/2022	Time lap of 5 days between DSC and OTR. No regulatory breach occurred during this period. The study have now recruited it's first participant.	Please Select
19/LO/1669	266322	The Rio Trial	14/01/2020	03/08/2021	12/12/2019	08/11/2021	09/11/2021	09/11/2021		Study team have assiduously screened a large number of patients , no eligible patient found.	Neither
20/NW/0113	269405	Dequalinium versus usual care antibiotics for the treatment of bacterial vaginosis	03/03/2021	09/09/2021	12/05/2020	15/10/2021	18/10/2021	23/02/2022	13/06/2022	Update from last submission ,no eligible patient was found for the study within the first patient recruitment window. First patient recruitment has now happened.	Please Select
21/SW/0049	283345	(EL4BS)	09/08/2021	05/10/2021	21/05/2021	29/12/2021	04/01/2022	10/03/2022		Sponsor delayed in the issuing of green light. Green light has now been issued	Sponsor
21/LO/0808	303028	OPTI BREECH	28/11/2021	07/12/2021	23/11/2021	13/12/2021	13/12/2021	07/01/2022	10/01/2022	None	Please Select
21/NI/0015	294144	Use of the HemoClear system for obstetric cell salvage: A pre-clinical proof of concept to cleanse blood salvaged in caesarean sections and vaginal delivery	10/02/2021	22/07/2021	10/02/2021	03/05/2021	23/07/2021	23/07/2021	27/07/2021		Please Select
21/WM/0196	297458	CP340 SUN-Study Investigation of patient benefits with a new supporting ostomy product and support service in patients with a newly stoma formation.	30/09/2021	25/11/2021	03/11/2021	16/12/2021	20/12/2021	21/01/2022	26/01/2022		Please Select
21/PR/0899	293493	Application of machine learning algorithm to identify patients at highest risk of atrial fibrillation for targeted screening	29/07/2021	02/12/2021	02/12/2021	06/08/2021	16/12/2021	16/12/2021		Withdrawal of funding from funder hence study cannot continue	Sponsor
18/NE/0296	248487	CArvediloL versus variceal Band ligation in primary pREvention of variceal bleeding in liver cirrhosis	12/09/2019	14/01/2022	19/10/2018	23/01/2020	25/02/2022	21/03/2022		Update from last submission. Difficult study to recruit to. Site have forwarded monthly logs in view of barriers to recruitment.	Neither
19/NW/0462	251756	Chronic Endometritis and Recurrent Miscarriage - The CERM trial	17/05/2021	04/02/2022	20/08/2019	05/01/2022	28/04/2022	28/04/2022	19/05/2022	Updated from last submission. First patient recruitment has now happened.	Please Select
21/PR/1738	300440	Efficacy of GLP-1 agonist Semaglutide in acute pulmonary embolisms: a biomarker-driven proof of concept open label phase II study	04/02/2022	09/03/2022	02/02/2022	10/04/2022	11/04/2022	11/04/2022	04/05/2022		Please Select
22/LO/0062	1004685	A Randomized, Double-Blind, Phase 3 Study of MK- 7684A Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants With Metastatic Non-Small Cell Lung Cancer	31/01/2022	16/03/2022	02/03/2022	16/06/2022	16/06/2022	17/06/2022		Screening is ongoing . No eligiblepatient found	Neither

21/SC/0317	302249	CONservative TReatment of Appendicitis in Children ? a randomised controlled Trial ? CONTRACT 2	18/10/2021	28/02/2022	21/12/2021	16/05/2022	16/05/2022	19/05/2022	08/06/2022		Please Select
21/SC/0363	301776	RESPOND study (Rescue for Emergency Surgery Patients Observed to uNdergo acute Deterioration) Work Package 3: Feasibility Trial	24/01/2022	31/03/2022	12/01/2022	29/04/2022	04/05/2022	14/06/2022	14/06/2022		Please Select
20/EM/0257	286724	A Prospective Study Evaluating the Safety and Effectiveness of EVARREST? Fibrin Sealant Patch in Controlling Mild or Moderate Hepatic Parenchyma or Soft Tissue Bleeding During Open Abdominal, Retroperitoneal, Pelvic and Thoracic (non-cardiac) Surgery in Pediatric Patients	29/11/2021	25/04/2022	14/12/2020	06/06/2022	06/06/2022			Awaiting green light to activate study from the sponsor.	Sponsor
21/EM/0281	262719	Calcium Supplementation for Prevention of Pre- eclampsia in High Risk Women: CaPE Trial	04/02/2022	09/05/2022	12/01/2022						Please Select
21/LO/0875	286685	Efficacy of doravirine + dolutegravir dual therapy in the context of antiretroviral therapy switch	01/04/2022	08/06/2022	18/02/2022						Please Select
21/LO/0410	274870	An open-label, non-randomized study of the impact on insulin sensitivity, lipid and endocrine profile following treatment with dolutegravir in HIV-negative volunteer		15/10/2021	06/07/2021	27/04/2022	27/04/2022	27/04/2022	13/06/2022		Please Select
21/LO/0783	297761	The effect of Biktarvy(B/F TAF) on whole body insulin sensitivity, lipid and endocrine profile in healthy volunteers	06/10/2021	01/12/2021	01/12/2021						Please Select